AmbioPharm, a global peptide contract development and manufacturing organisation (CDMO), is set to complete the expansion of its Shanghai Building 2 facility next month. The project will add nearly 75,000 square feet of commercial-scale manufacturing space. The expansion includes multiple
Made Scientific, a U.S.-based contract development and manufacturing organisation (CDMO) specialising in cell therapies, has announced the creation of its first Scientific Advisory Board (SAB). The board comprises Miguel Forte, M.D., Ph.D., Paul K. Wotton, Ph.D., Shishir Gadam, Ph.D., and
Sai Life Sciences Limited, a contract research, development, and manufacturing organisation (CRDMO), has completed Phase II of its new Production Block 11 (PB-11) at its flagship API manufacturing facility in Bidar, India. The expansion increases the block’s combined reactor capacity
George Medicines, a late-stage biopharma company, has partnered with Piramal Pharma Solutions (PPS), a global CDMO, to develop WIDAPLIK, a new drug for the treatment of hypertension in adults. The therapy has received FDA approval, marking it as the first
Altasciences, a contract research and contract development and manufacturing organisation (CRO/CDMO), has announced a strategic collaboration with Evidence Matters, a company specialising in clinical trial data science and document engineering. The partnership centres on Evidence Matters’ patent-pending Text Engineering technology
Cold Chain Technologies (CCT) has reinforced its commitment to the Asia Pacific (APAC) market with a series of investments and partnerships. The company said the moves are designed to combine global expertise with local capabilities for customers in pharmaceuticals, airlines,
Asymchem, a global CDMO, has announced the expansion of its flow chemistry capabilities at its Sandwich, UK facility. The development marks the first use of the company’s proprietary, regulatory-compliant flow equipment in the Western market. The newly commissioned suite features
Daewoong Bio has launched its new Bio-Center in Hyangnam, South Korea, designed to provide end-to-end contract manufacturing services for microbial-based biopharmaceuticals. The facility integrates both drug substance (DS) and drug product (DP) manufacturing. DS manufacturing includes fermentation at up to
Hongene Biotech Corporation, a contract development and manufacturing organisation (CDMO) specialising in nucleic acid therapeutics, has signed a non-exclusive licensing agreement with the UMass Chan Medical School. The deal will allow Hongene to produce and supply extended nucleic acid (exNA)
“The greatest opportunity at Teva is our innovative pipeline. We’re really leaning in on our innovative pipeline as an integral part of our pivot to growth strategy.” This is the ambitious vision of Dr Eric Hughes, Executive Vice President of
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
